Liver Cirrhoses Clinical Trial
Official title:
Interventional Devascularization Plus HVPG‐Guided Carvedilol Therapy vs TIPS for the Prevention of Gastric Variceal Rebleeding in Patients With Liver Cirrhosis: A Prospective, Randomized, Controlled Trial
Gastric varices (GV) are present in around 20% of patients with cirrhosis. Bleeding from GV
accounts for 10-20% of all variceal bleeding. For the prevention of gastric variceal
bleeding, TIPS or BRTO as firstline treatments were suggested.
No randomized trials have compared BRTO with other therapies. BRTO and its variations might
increase portal pressure and might worsen complications, such as ascites or bleeding from EV.
In this regard, if NSBB is combined with BRTO and its variations (we called interventional
devascularization) for those HVPG responders, the drawbacks of interventional
devascularization might be overcome. Therefore, the investigators conducted this RCT to
compare the effectiveness and safety of TIPS with those of interventional devascularization
in the prevention of rebleeding from gastric varices.
Status | Not yet recruiting |
Enrollment | 212 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Liver cirrhosis diagnosed by clinical examination, imaging or biopsy - Patients with a previous history of variceal hemorrhage - Gastric variceal confirmed by an endoscopic examination, including IGV1 or IGV2 - Aged 18 to 75 years - Adequate liver and kidney function, including Child-Turcotte-Pugh score < 12, MELD score <19, and serum creatinine less than 2 times the upper limit of normal. Exclusion Criteria: - Active variceal bleeding - Esophageal variceal, including GOV1 or GOV2 type, mainly esophageal varices; - Refractory ascites - Patients with contraindication to treatment of TIPS, including congestive heart failure, NYHA III and IV, pulmonary arterial hypertension(>50mmHg), polycystic liver, intrahepatic duct dilatation, spontaneous bacterial peritonitis, hepatic encephalopathy - Patients with contraindication to treatment of Carvedilol, including asthma, insulin-dependent diabetes, peripheral vascular diseases - Child-Turcotte-Pugh score >=12, or MELD score >=19 - Budd-Chiari syndrome - The main portal vein thrombosis is greater than 50% - Malignancies - An uncontrolled infection - Previously treated with TIPS, splenectomy pericardia vascular disconnection, or surgical shunts - HIV or HIV related illness - Allergic to contrast agent - Lactating or pregnant - Non-compliant patients |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Fourth Military Medical University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cumulative incidence of gastric variceal rebleeding | Confirmed by endoscopy | 12 months | |
Secondary | Cumulative incidence of variceal hemorrhage related death | 12 months | ||
Secondary | Cumulative incidence of hepatic encephalopathy (HE) | HE is classified as covert HE and overt HE | 12 months | |
Secondary | Cumulative incidence of death | all cause mortality | 12 months | |
Secondary | Cumulative incidence of adverse events | number of adverse events and adverse reactions in each arm | 12 months | |
Secondary | Correlation between hepatic venous pressure gradient response and cardiac index response to Carvedilol | Investigate non-invasive tools for risk stratification | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03219372 -
Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence
|
Phase 2 | |
Recruiting |
NCT03624517 -
Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices
|
Phase 4 | |
Recruiting |
NCT04057287 -
Risk Factors of Liver Fibrosis Among First Degree Relatives of Patients With NASH Related Cirrhosis (NRC)
|
||
Recruiting |
NCT04089878 -
"To Study the Impact of Balloon-occluded Retrograde Transvenous Obliteration (BRTO)/Plug Assisted Retrograde Transvenous Obliteration (PARTO) Mediated Portal Flow Modulation in Reduction of Ammonia and Improvement in Organ Volume and Functionality in Patients of Cirrhosis With LR Shunt
|
N/A | |
Completed |
NCT04212286 -
Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC
|
N/A | |
Completed |
NCT04474743 -
Malnutrition in Chronic Gastrointestinal Diseases, Cross-sectional Study
|
||
Recruiting |
NCT03694691 -
Developing Viability Index for Machine Perfused Livers
|
N/A | |
Terminated |
NCT04072601 -
Statins for Prevention of Disease Progression and Hospitalization in Liver Cirrhosis
|
Phase 4 | |
Terminated |
NCT03878563 -
Alterations in Intestinal Mucosal Barrier Visualized by Confocal Laser Endomicroscopy in Liver Cirrhosis: a Pilot Trial (AMBIC)
|
||
Terminated |
NCT04160039 -
Early Cycle Ergometry for Critically-Ill Liver Failure Patients in a Transplant Intensive Care Unit
|
N/A | |
Recruiting |
NCT04191369 -
EGD vs EUS in Diagnosing Portal Hypertension in Cirrhotic Patients.
|
N/A | |
Completed |
NCT03083925 -
Viatorr CX Case-control Study for Complications of Portal Hypertension
|
||
Not yet recruiting |
NCT03855709 -
Antibiotic-resistant Bacterial Infection of Hepatic Patients
|
||
Recruiting |
NCT02484573 -
Evaluation of Intestinal Permeability in Cirrhotic Patients Before and After Treatment With Non-selective Beta Blocker (Propranolol)
|
N/A | |
Recruiting |
NCT04357600 -
Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B
|
Phase 1/Phase 2 | |
Completed |
NCT03156426 -
Prognostic Biomarkers For Acute Kidney Injury In Liver Cirrhosis
|
||
Active, not recruiting |
NCT03868397 -
Preoperative Portal and Splanchnic Flow Measurement Using MRI
|
N/A | |
Terminated |
NCT03650660 -
Concordance Between Echocardiographic Assessment Performed in the Initial Phase of Decompensated Cirrhosis With Edema and Ascites by an Expert Intensive Care Physician and a Non-expert Gastroenterologist
|
||
Completed |
NCT03871894 -
Indirect Calorimeter Based Study in Patients With Liver Cirrhosis
|
N/A | |
Completed |
NCT03283176 -
Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without Ribavirin
|